DelveInsight’s “Neuroblastoma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Neuroblastoma, historical and forecasted epidemiology as well as the Neuroblastoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Neuroblastoma marketis expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Neuroblastoma pipeline products will significantly revolutionize the Neuroblastoma market dynamics.
Neuroblastoma is an embryonal malignancy of the sympathetic nervous system arising from neuroblasts (pluripotent sympathetic cells). It is derived from two words i.e. “neuro” means nerves and “blastoma” refers to the tumor affecting the immature or developing cells. It originates in the adrenal medulla and paraspinal or periaortic regions where sympathetic nervous system tissue is present.
Stages of neuroblastoma determine the extent of spread of the tumor in the patients, and the disease is staged on the basis of results of physical exams, imaging tests, and biopsies of the main tumor and other tissues.
Some of the key facts of the Neuroblastoma Market Report:
The Neuroblastoma market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
In December 2021, Phase II data of hu14.18K322A was published at ASCO journal, data showed improved outcome in children with newly diagnosed high-risk neuroblastoma treated with chemoimmunotherapy
In September 2021, Y-mAbs Therapeutics presented data from phase II trial of Naxitamab for the treatment of refractory/relapsed high-risk neuroblastoma
According to a study conducted by Shohet et al., the median time to relapse is around 1.5 years from diagnosis
Key Neuroblastoma Companies: Clarity Pharmaceuticals, Y-mabs therapeutics, Eli Lilly, LaboratorioElea Phoenix, K C Pharmaceuticals, AutolusTherapeutics, and others
Neuroblastoma market report covers a descriptive overview and comprehensive insight of the Neuroblastoma Epidemiology and Neuroblastoma market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
The Neuroblastoma market report provides insights on the current and emerging therapies.
Neuroblastoma market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Neuroblastoma market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Neuroblastoma market.
The Neuroblastoma market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
Total Prevalence of Neuroblastoma
Prevalent Cases of Neuroblastoma by severity
Gender-specific Prevalence of Neuroblastoma
Diagnosed Cases of Episodic and Chronic Neuroblastoma
The dynamics of the Neuroblastoma market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as LY 3295668, Racotumomab, and others during the forecasted period 2019-2032.
Understanding of neuroblastoma biology deepens, our approaches to therapy for this disease continue to evolve Improved risk stratification and the use of predictive biomarkers will aid in treatment selection for patients with neuroblastoma, and it is expected that future treatments will be associated with greater efficacy and less toxicity
Table of Contents
1. Neuroblastoma Market Report Introduction
2. Executive Summary for Neuroblastoma
3. SWOT analysis of Neuroblastoma
4. Neuroblastoma Patient Share (%) Overview at a Glance
5. Neuroblastoma Market Overview at a Glance
6. Neuroblastoma Disease Background and Overview
7. Neuroblastoma Epidemiology and Patient Population
8. Country-Specific Patient Population of Neuroblastoma
9. Neuroblastoma Current Treatment and Medical Practices